Cell & Gene Therapies

CAR‑T, CRISPR, in vivo delivery, manufacturing, and long‑term follow‑up.

  • 4 Tracked terms
  • Last 30 days Feed window

What this topic collects on

An article joins this feed when it matches these terms. Each one is also a search of its own.

Latest in Cell & Gene Therapies


openpr.com > news > 4636057 > car-t-clinical-trial-pipeline-gains-momentum-180-companies

CAR-T Clinical Trial Pipeline Gains Momentum: 180+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

2+ day, 1+ hour ago   (60+ words) CAR-T Clinical Trial Pipeline Gains Momentum: 180+ Companies openPR.com CAR-T Clinical Trial Pipeline Gains Momentum: 180+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight Press release from: ABNewswire Permanent link to this press release: You can edit or delete your…...


insideprecisionmedicine.com > topics > oncology > crispr-activation-tool-uncovers-genes-linked-to-lymphoma-drug-resistance

CRISPR Activation Tool Uncovers Genes Linked to Lymphoma Drug Resistance

2+ day, 3+ min ago   (505+ words) Inside Precision Medicine A new whole-genome CRISPR screening platform has helped researchers identify a previously unknown gene causing lymphoma cells to become resistant to a widely used cancer drug, as well as several genes that can accelerate tumor growth. Published…...


wcpo.com > videos > news > local-news > christ-hospital-trial-targets-genetic-fix-for-high-cholesterol

Christ Hospital trial targets genetic fix for high cholesterol

1+ day, 20+ hour ago   (21+ words) WCPO 9 News Christ Hospital trial targets genetic fix for high cholesterol...


eurekalert.org > news-releases > 1143775

Gene that drives blood cancer drug resistance uncovered with new CRISPR activation tool

1+ day, 23+ hour ago   (437+ words) Researchers used a powerful new guide RNA library, Partita, to find genes that help lymphoma cells escape treatment and accelerate tumor growth image: L-R: Dr Eddie La Marca, Prof Marco Herold; L-R: Dr Yexuan Deng, Dr Margaret Potts, Dr Sarah…...


miragenews.com > crispr-tool-unveils-gene-behind-blood-cancer-1747136

CRISPR Tool Unveils Gene Behind Blood Cancer Drug Resistance

1+ day, 23+ hour ago   (338+ words) GLOBAL: Researchers have uncovered a previously unknown gene causing resistance to a leading blood cancer drug and several genes that accelerate lymphoma growth by using a powerful new CRISPR activation library. Traditional CRISPR is a genetic engineering tool that allows…...


news-medical.net-medical.net

iPSC-derived CAR γδ T cells for liver cancer

2+ day, 6+ hour ago   (374+ words) Autologous chimeric antigen receptor (CAR) T cell therapies are now a part of standard treatment protocol for hematological malignancies. Despite this, they are deeply constrained by elevated costs and delayed access for patients. Allogeneic donor-derived CAR T cells make off-the-shelf…...


newsnetwork.mayoclinic.org > discussion > study-shows-reprogramming-thyroid-tumors-may-improve-car-t-cell-therapy

Study shows reprogramming thyroid tumors may improve CAR-T cell therapy

2+ day, 7+ hour ago   (592+ words) ROCHESTER, Minn. — Mayo Clinic researchers have identified a strategy that could help chimeric antigen receptor-T cell therapy, or CAR-T cell therapy, overcome a major barrier to treating solid tumors: Cancer cells can change in ways that allow them to hide…...


medium.com > @Gene_Therapy_Edge > the-fratricide-problem-why-car-t-struggled-against-t-cell-cancers-and-how-scientists-are-finally-21813d8f66de

The Fratricide Problem: Why CAR-T Struggled Against T-Cell Cancers, and How Scientists Are Finally…

2+ day, 20+ hour ago   (136+ words) The Fratricide Problem: Why CAR-T Struggled Against T-Cell Cancers, and How Scientists Are Finally Solving It When the Cure and the Cancer Look the Same CAR-T cell therapy has quietly become one of …...


finance.yahoo.com > healthcare > articles > car-t-cell-therapy-acute-085400814.html

CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Market Set for Strong Growth Through 2036, Driven by Next-Generation Innovation and Expanding Patient Access

4+ day, 15+ hour ago   (442+ words) ALL care is shifting toward CAR-T, creating opportunities in earlier treatment, off-the-shelf platforms and CD7 targeting, while relapse, toxicity and manufacturing remain key unmet needs. Dublin, Sept. 16, 2026 (GLOBE NEWSWIRE) -- "CAR T-Cell Therapy for Acute Lymphoblastic Leukemia - Market Insight, Epidemiology, and Market…...


prnewswire.com > news-releases > iaso-bios-cd20-targeted-in-vivo-car-t-therapy-iaso208-receives-fda-ind-clearance-302880431.html

IASO Bio's CD20-Targeted In Vivo CAR-T Therapy IASO208 Receives FDA IND Clearance

4+ day, 7+ hour ago   (110+ words) Sep 16, 2026, 05:47 ET — IASO208 is the first China-originated lentiviral vector-based in vivo CAR-T therapy to receive FDA IND clearance — Supported by early clinical data from an investigator-initiated trial in China, IASO208 is expected to advance directly into a Phase 1b clinical study in the…...